RBC maintains USD 6.00 target for Pyxis Oncology stock

Published on 10/16/2026 at 04:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 1 offering brought USD 110.0 million upfront. Pyxis Oncology stock has a USD 114.0 million market value on October 15, 2026.

Financing and clinical milestones

Pyxis Oncology secured USD 110.0 million in upfront gross proceeds on October 1, 2026.
GAAP net loss reached USD 25.35 million for the quarter ended June 30, 2026.
Pyxis Oncology had a USD 114.0 million market capitalization on October 15, 2026.

PYXS, US7473241013, Illustration mit AI erstellt.

Pyxis Oncology (ISIN US7473241013) retained a USD 6.00 price target and Buy rating from RBC Capital on October 7, 2026, according to Markets Insider. The analyst update followed Pyxis Oncology's October 1 closing of a public offering that generated USD 110.0 million in upfront gross proceeds, according to Yahoo Finance.

Financing sets the near-term frame

The offering included 36,047,919 common shares priced at USD 2.90 and pre-funded warrants for 1,883,121 shares. It also included warrants for 49,310,352 common shares with a USD 3.50 exercise price, creating a potential total of USD 282.6 million in gross proceeds if exercised in full, according to Yahoo Finance.

Three dated funding milestones

On October 1, 2026, Sidley Austin described the offering as generating USD 110.0 million in gross proceeds. On October 2, 2026, Yahoo Finance reported the closing and potential USD 282.6 million total. On October 7, 2026, RBC Capital maintained its USD 6.00 target, as reported by Markets Insider.

What does the financing mean for cash?

The financing expands Pyxis Oncology's funding base for MICVO and the planned Headliner Phase 3 trial, but the warrants depend on stockholder approval of an authorized-share increase. The company reported a GAAP net loss of USD 25.35 million for the quarter ended June 30, 2026, compared with a USD 18.35 million GAAP net loss in the year-earlier quarter, according to Markets Insider.

Clinical dates shape the next test

Pyxis Oncology plans to disclose updated data from its MICVO combination study in the fourth quarter of 2026. The company also expects overall survival data from its Phase 1 monotherapy study in the first half of 2027, according to Yahoo Finance. Those milestones give the financing a defined clinical timetable rather than a purely balance-sheet purpose.

Valuation stays tied to execution

PYXS was last at USD 1.80 on Nasdaq on October 15, 2026 at 4:00 p.m. ET. The stock's market capitalization was USD 114.0 million on that date, while its 52-week range was USD 1.03 to USD 5.55. For investors, the gap between the USD 6.00 analyst target and the latest quoted level leaves the clinical data schedule as the central execution test.